Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.021
Neutral
RSI(14)
51.410
Neutral
STOCH(KDJ)(9,3,3)
34.321
Neutral
ATR(14)
0.378
Low Volatility
CCI(14)
-26.315
Neutral
Williams %R
49.995
Neutral
TRIX(12,20)
0.130
Sell
StochRSI(14)
85.785
Buy
Bicycle Therapeutics PLC
BCYC6.950USD
-0.240-3.34%
Market hours （ET）Quotes delayed by 15 min
346.59MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Bicycle Therapeutics PLC
Currency: USD Updated: 2025-12-22Key Insights
Bicycle Therapeutics PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 54/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.58.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bicycle Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Buy
Current Rating
21.583
Target Price
+191.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bicycle Therapeutics PLC Highlights
StrengthsRisks
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 35.27M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 35.27M.
Overvalued
The company’s latest PE is -1.98, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 39.22M shares, increasing 0.08% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 9.37K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Bicycle Therapeutics PLC is 7.78, ranking 83/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 11.73M, representing a year-over-year increase of 338.49%, while its net profit experienced a year-over-year increase of 16.33%.
Score
Financials
9.88
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.38
Operational Efficiency
3.13
Growth Potential
10.00
Shareholder Returns
7.53
Bicycle Therapeutics PLC's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Bicycle Therapeutics PLC is 7.66, ranking 98/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.98, which is -14.19% below the recent high of -1.70 and -324.23% above the recent low of -8.41.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 54/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Bicycle Therapeutics PLC is 7.86, ranking 266/404 in the Biotechnology & Medical Research industry. The average price target for Bicycle Therapeutics PLC is 16.00, with a high of 44.00 and a low of 6.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
21.583
Target Price
+191.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Bicycle Therapeutics PLC
BCYC
14
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Bicycle Therapeutics PLC is 6.38, ranking 274/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.91 and the support level at 6.38, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.018
Sell
MA10
7.191
Sell
MA20
7.148
Sell
MA50
7.271
Sell
MA100
7.359
Sell
MA200
7.791
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Bicycle Therapeutics PLC is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 114.58%, representing a quarter-over-quarter decrease of 9.44%. The largest institutional shareholder is PRFDX, holding a total of 1.38M shares, representing 2.77% of shares outstanding, with 13.79% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Baker Bros. Advisors LP
Forbion Capital Partners
Armistice Capital LLC
Westfield Capital Management Company, L.P.
Invus Public Equities Advisors, LLC
Long Focus Capital Management LLC
Candriam Luxembourg S.A.
Acadian Asset Management LLC
Candriam Belgium S.A.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Bicycle Therapeutics PLC is 4.25, ranking 104/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.53
VaR
+5.63%
240-Day Maximum Drawdown
+59.30%
240-Day Volatility
+69.53%
Return
Best Daily Return
60 days
+7.62%
120 days
+7.62%
5 years
+28.33%
Worst Daily Return
60 days
-10.19%
120 days
-10.19%
5 years
-38.69%
Sharpe Ratio
60 days
+0.03
120 days
+0.37
5 years
-0.10
Risk Assessment
Maximum Drawdown
240 days
+59.30%
3 years
+78.48%
5 years
+89.91%
Return-to-Drawdown Ratio
240 days
-0.89
3 years
-0.32
5 years
-0.17
Skewness
240 days
+0.13
3 years
+0.41
5 years
-0.14
Volatility
Realised Volatility
240 days
+69.53%
5 years
+77.49%
Standardised True Range
240 days
+7.59%
5 years
+21.63%
Downside Risk-Adjusted Return
120 days
+57.53%
240 days
+57.53%
Maximum Daily Upside Volatility
60 days
+45.53%
Maximum Daily Downside Volatility
60 days
+43.84%
Liquidity
Average Turnover Rate
60 days
+0.41%
120 days
+0.47%
5 years
--
Turnover Deviation
20 days
-48.96%
60 days
-44.11%
120 days
-35.11%
Peer Comparison
Biotechnology & Medical Research
Bicycle Therapeutics PLC
BCYC
7.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Bicycle Therapeutics PLC?
The TradingKey Stock Score provides a comprehensive assessment of Bicycle Therapeutics PLC based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Bicycle Therapeutics PLC’s performance and outlook.
How do we generate the financial health score of Bicycle Therapeutics PLC?
To generate the financial health score of Bicycle Therapeutics PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Bicycle Therapeutics PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Bicycle Therapeutics PLC.
How do we generate the company valuation score of Bicycle Therapeutics PLC?
To generate the company valuation score of Bicycle Therapeutics PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Bicycle Therapeutics PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Bicycle Therapeutics PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Bicycle Therapeutics PLC.
How do we generate the earnings forecast score of Bicycle Therapeutics PLC?
To calculate the earnings forecast score of Bicycle Therapeutics PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Bicycle Therapeutics PLC’s future.
How do we generate the price momentum score of Bicycle Therapeutics PLC?
When generating the price momentum score for Bicycle Therapeutics PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Bicycle Therapeutics PLC’s prices. A higher score indicates a more stable short-term price trend for Bicycle Therapeutics PLC.
How do we generate the institutional confidence score of Bicycle Therapeutics PLC?
To generate the institutional confidence score of Bicycle Therapeutics PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Bicycle Therapeutics PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Bicycle Therapeutics PLC.
How do we generate the risk management score of Bicycle Therapeutics PLC?
To assess the risk management score of Bicycle Therapeutics PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Bicycle Therapeutics PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Bicycle Therapeutics PLC.
